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Abstract
Background/Aim. Multiple sclerosis (MS) is an immune-
mediated central nervous system disease characterized by
inflammation, demyelination and axonal degeneration. Cy-
tokines are proven mediators of immunological process in
MS. The aim of this study was to investigate whether there
is a difference in the production of the tumor necrosis fac-
tor alpha (TNF-alpha) and interleukin-4 (IL-4) in cerebro-
spinal fluid (CSF) and plasma in the MS patients and the
controls (other neurological non-inflammatory diseases) and
to determine a possible difference in these cytokines in
plasma and CSF in different clinical forms of MS. Meth-
ods. This study involved 60 consecutive MS patients – 48
patients with relapsing-remitting MS (RRMS) and 12 pa-
tients with secondary progressive MS (SPMS). The control
group consisted of 20, age and sex matched, non-
immunological, neurological patients. According to the
clinical presentation of MS at the time of this investigation,
34 (56.7%) patients had relapse (RRMS), 14 (23.3%) were in
remission (RRMS), while the rest of the patients, 12
(20.0%), were SPMS. TNF-alpha and IL-4 concentrations
were measured in the same time in CSF and plasma in the
MS patients and the controls. Extended disability status
score (EDSS), albumin ratio and IgG index were deter-
mined in all MS patients. Results. The MS patients had sig-
nificantly higher CSF and plasma levels of TNF-alpha than
the controls (p < 0.001 for both samples). IL-4 CSF levels
were significantly lower in the MS patients than in the con-
trols (p < 0.001), however plasma levels were similar. The
patients in relapse (RRMS) and with progressive disease
(SPMS) had higher concentrations of CSF TNF-alpha levels
than the patients in remission (p < 0.001). IL-4 CSF levels
in relapse (RRMS) and SPMS groups were lower than in the
patients in remission. The patients in remission had an un-
measurable plasma TNF-alpha level and the patients with
SPMS had significantly lower IL-4 levels in plasma than the
patients in relapse and remission (p < 0.001). The only sig-
nificant correlation between cytokine level with either
EDSS, or albumin ratio, or IgG index, was found between
CSF TNF-alpha levels and albumin ratio in the patients with
relapse (R square = 0.431, p < 0.001).  Conclusion. Ac-
cording to the obtained data MS relapse was characterized
by high concentrations of TNF-alpha in CSF and plasma
and low concentrations of I L - 4  i n  C S F .  R e m i s s i o n  w a s
characterized by high concentrations of IL-4 and low con-
centrations of TNF-alpha both in CSF and plasma. SPMS
was characterized with lower concentrations of TNF-alpha
and IL-4 compared to relapse, both in CSF and plasma.
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Apstrakt
Uvod/Cilj. Multipla skleroza (MS) je imunološki posredovana
bolest centralnog nervnog sistema koju karakterišu inflamacija,
demijelinizacija, degenaracija aksona i glioza. Citokini su važni
medijatori imunoloških procesa kod MS. Cilj ove studije bio je
da se ispita postojanje razlike u produkciji inflamacijskog cito-
kina faktora nekroze tumora alfa (TNF-alfa) i antiinflamacij-
skog citokina interleukina 4 (IL-4) u likvoru i plazmi bolesnika
sa različitim kliničkim faktorima MS i kod bolesnika sa drugim
neurološkim neinflamacijskim oboljenjima (kontrolna grupa).
Metode. U studiju je bilo uključeno 60 bolesnika sa MS, 48 sa
relapsno-remitentnom MS (RRMS) i 12 bolesnika sa sekundar-
no progresivnom MS (SPMS). Kontrolnu grupu je sačinjavalo
20 bolesnika sa neurološkim, neimunološkim bolestima. U
vreme ispitivanja, 34 (56,7%) bolesnika bilo je u fazi pogorša-
nja, 14 (23,3%) u fazi remisije, dok je 12 (20%) bolesnika imalo
SPMS. Citokini TNF-alpha i IL-4 određivani su istovremeno u
plazmi i likvoru bolesnika sa MS i kontrolne grupe. Nivo neu-
rološkog poremećaja, izmeren korišćenjem  The ExpandedStrana 152 VOJNOSANITETSKI PREGLED Volumen 69, Broj 2
Obradović D, et al. Vojnosanit Pregl 2012; 69(2): 151–156.
Disability Status Scale (EDSS), albuminski koeficijent i IgG in-
deks određivani su kod svih bolesnika sa MS. Rezultati. Bole-
snici sa MS imali su značajno više koncentracije TNF-alfa i u li-
kvoru i u plazmi, u poređenju sa bolesnicima kontrolne grupe
(p < 0,01). Koncentracija IL-4 u likvoru bila je značajno niža
kod bolesnika sa MS, nego kod bolesnika kontrolne grupe
(p < 0,01), dok su koncentracije plazmatskih vrednosti bile slič-
ne. Bolesnici u fazi pogoršanja (RRMS) i sa SPMS imali su više
koncentracije TNF-alfa u likvoru, nego bolesnici u fazi remisije
bolesti (RRMS), (p < 0,01). Koncentracija IL-4 u likvoru bila je
niža kod bolesnika sa RRMS u fazi pogoršanja i SPMS, nego
kod bolesnika koji su bili u remisji bolesti (p < 0,01). Kod bole-
snika u remisiji nije nađen TNF-alfa u plazmi, dok su bolesnici
sa SPMS imali značajno niže koncentracije IL-4 u plazmi u po-
ređenju sa bolesnicima u fazi pogoršanja i u remisiji (p < 0.01).
Jedina statistički značajna korelacija nađena je između koncen-
tracije TNF-alfa u likvoru i albuminskog koeficijenta i to kod
bolesnika u fazi pogoršanja bolesti (R square = 0,431, p < 0,01).
Zaključak. Prema rezultatima našeg istraživanja, pogoršanje
MS karakterišu visoke koncentracije TNF-alfa u likvoru i plaz-
mi i niske koncentracije IL-4 u likvoru. Remisiju bolesti karak-
terišu visoke koncentracije IL-4 i niske koncentraije TNF-alfa i
u plazmi i u likvoru. Progresivnu formu (SPMS) karakterišu ni-
že koncentracije TNF-alfa i IL-4 u poređenju sa relapsom, i to i
u plazmi i u likvoru.
Ključne reči:
multipla skleroza; faktor nekroze tumora; interleukin-4;
plazma; cerebrospinalna tečnost; bolest, progresija;
lečenje, ishod.
Introduction
Multiple sclerosis (MS) is a central nervous system
(CNS) disease characterized by inflammation, demyelination
and axonal degeneration. The etiology of MS is still un-
known. The results of numerous experimental and clinical
studies support the thesis of MS being immunologically me-
diated disease
 1–4. According to currently accepted theory,
autoreactive Th1 cells (CD4+) directed at myelin or oligo-
dendrocyte antigens, initiate aberrant immune response in
peripheral blood, away from immunologically protected and
privileged CNS. Through interaction with adhesive mole-
cules Th1 cells cross the damaged blood-brain barrier, inside
the CNS they have to be reactivated and in further interaction
between Th1 cells, macrophages, residential CNS cells and B
cells, numerous inflammatory, anti-inflammatory cytokines,
auto-antibodies, oxidative species and enzymes are pro-
duced
 1. Recently, the presence of Th17 cells has been ac-
knowledged, characterized by interleukin (IL)-17A produc-
tion, another potent proinflamatory cytokine, which causes
upregulation of several inflammatory cytokines such as the
tumor necrosis factor-alpha (TNF-alpha), IL-1beta, IL-6, IL-
8
 3. They have a potential to damage myelin, directly or indi-
rectly with consequent axonal damage. So, cytokines are im-
portant mediators of immune response in MS
 5, and possible
shifting toward Th1 and Th17, with the down regulation of
Th2 cytokine response, might be one of the important causes
of ongoing inflammatory damage in MS. However, an inter-
play between immune mediated inflammation and neurode-
generation seems to play crucial role in MS development and
progression
 6.
Clinically, MS is characterized by the phases of remis-
sions and relapses in the majority of patients, relapsing-
remitting MS (RRMS). In so calledthe time course, most of
these patients develop secondary progressive form of MS –
secondary progressive MS (SPMS), while the smallest pro-
portion of patients is characterized by the progressive course
from the onset – primary progressive MS (PPMS). Some
studies 
7, 8 suggest that different immunopathological mecha-
nisms might be involved in the development of different MS
types. That might explain different course and prognosis of
the disease, necessity of different therapeutic approach in
different MS types and unresponsiveness of SPMS and
PPMS to current immunomodulatory treatment
 9.
There are few studies that compare concentrations of
cytokines both in cerebrospinal fluid (CSF) and plasma in
MS patients
 7, 10 and to the best of our knowledge none that
compares concentrations of cytokines in both compart-
ments, in clinically different stages of MS. TNF-alpha is
one of the most potent inflammatory cytokines with the
confirmed role in direct myelin damage
 11. It enhances ex-
pression of adhesion molecules on endothelial cells and
lymphocytes
 12, induces secretion of interferon gamma and
other inflammatory cytokines and chemokines
 13, and indi-
rectly through activation of macrophages and microgial
cells, stimulates the production of reactive oxidative spe-
cies, nitric oxide and lytic enzymes
 14. On the other hand,
IL-4 is an anti-inflammatory Th2 cytokine with the pro-
posed protective role in MS
 15–18.
Hence, the aim of our study was to investigate
whether there is a difference in the production of TNF-alfa
and IL-4 in CSF and plasma in MS patients and patients
with other non-inflammatory neurological diseases, to de-
termine a possible difference in the production of these
cytokines both in plasma and CSF in different stages of MS
– relapse, remission, progressive phase, and to evaluate a
correlation between cytokine concentrations in CSF and
plasma and clinical impairment, albumin ratio, intrathecal
IgG synthesis.
Methods
Sixty consecutive patients from the Department of
Neurology, Military Medical Academy, Belgrade were en-
rolled in the study after obtaining a permission of the Ethi-
cal Committee of the Military Medical Academy in Bel-
grade. All of them had clinically definite diagnosis of MS
according to Poser criteria
 19 and had either exacerbation
(relapse), or SPMS or clinically stable disease (remission).
None of them were on immunosuppressive treatment at
least 3 months prior the study. Clinical assessment was per-
formed by using an expanded disability status scale (EDSS)
score
 20. The control group consisted of 20 age and gender
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eases (epilepsy, spasmodic torticolis and hereditary neu-
ropathy).
In all the patients, CSF and blood samples were ob-
tained and after spinning stored at -70ºC for cytokine analy-
sis. Cytokine analysis was done by the ELISA method (Gen-
zyme, Predicta), according to the written instructions. Apart
from cytokine analysis, blood and CSF samples were used
for evaluation of albumin ratio and IgG index. Albumin ratio
was calculated according to the formula: CSF albumin/serum
albumin, while IgG index was calculated by using the for-
mula – IgG CSF / IgG serum : albumin CSF / albumin serum
(normal values: < 5.7 and < 0.7 respectively)
 21.
Discrete variables are shown as counts and percentages.
Continuous variables are presented as median with the inter-
quartile range (iqr) (25-75 percentile). TNF-alpha and IL-4
CSF and plasma levels were compared between the MS pa-
tients and the control group by the Mann-Whitney test.
Comparison of TNF-alpha and IL-4 CSF and plasma levels
within the MS subgroups were done by using Kruskal-Wallis
test. A correlation between TNF-alpha CSF levels and albu-
min ratio was presented as a linear regression curve. A p-
value of less than 0.05 was accepted as statistically signifi-
cant.
Results
The majority of the patients were classified as RRMS
– 48 (80.0%) and 12 patients (20.0%) had secondary pro-
gressive disease (SPMS). According to the clinical pres-
entation at the time of this investigation, 34 (56.7%) pa-
tients had relapse, 14 (23.3%) were in remission, while the
rest of the patients were in secondary progressive phase of
MS 12 (20.0%). In our study group female predominance
was present (60.0%), average age was 43.5 ± 3.2 the dis-
ease duration was 5.6  ±  2. Average EDSS in our group
was 3.8 ± 0.7.
Concentrations of TNF-alpha and IL-4 in CSF and
plasma for MS patients and controls analyzed in this study
are shown in Table 1.
TNF-alpha was detected in CSF of all MS patients and
in none of the patients of the control group. In plasma, it was
detected in 38 (63.3%) of MS patients, and in 7 patients
(35.0%) of the control group, with significantly higher values
in the MS group (p < 0.001). There was no significant differ-
ence in TNF-alpha concentrations in CSF and plasma in the
MS group.
In relation to clinical presentation of MS, higher con-
centration of TNF-alpha in CSF was found in the relapse
group than in SPMS (without a statistical significance be-
tween these two groups), and the lowest in the remission
phase of the disease (p < 0.001). TNF-alpha was not de-
tected in plasma of the patients in remission. However,
TNF-alpha was detected in plasma in the majority of re-
lapse patients, 30 (88.2%), and in all the patients with
SPMS, without a significant difference between these two
groups.
IL-4 was detected in plasma of 37 (61.7%) and in CSF
of 54 (90%) of MS patients and in all the patients in the
control group, in both CSF and plasma (Table 1). IL-4 was
significantly lower in CSF of the MS group compared with
the controls (p < 0.001), while there was no difference be-
tween its' plasma concentrations in the two groups
(p  =  0.154). CSF concentration of IL-4 was significantly
lower as compared with plasma concentration in MS group
(p < 0.05).
All the patients with progressive MS (SPMS), those in
remission and 70% of the relapse patients had detectable
CSF levels of IL-4.  The highest CSF concentration of IL-4
was found in the remission group and it was significantly
higher than in the relapse and progressive MS groups.
We did not find a correlation between either of the cy-
tokine and EDSS.
On the other hand, we found a significant linear corre-
lation between albumin ratio and TNF-alpha concentration in
CSF of the relapse MS group (Figure 1). No correlation was
found between IgG index and cytokine concentrations in the
CSF and plasma of the MS patients.
Table 1
Concentrations of TNF-alpha and IL-4 in cerebrospinal fluid (CSF) and plasma of the multiple sclerosis (MS) patients and the control group
TNF–alpha IL–4
MS group Control group MS group Control group Body fluid
Median (IQR)
(pg/mL)
Detectability
(%)
Median (IQR)
(pg/mL)
Detectability
(%)
Median (IQR)
(pg/mL)
Detectability
(%)
Median (IQR)
(pg/mL)
Detectability
(%)
CSF
  All patients
  Relapse
  SPMS
  Remission
  p
Plasma
  All patients
  Relapse
  SPMS
  Remission
  p
198.8 (88.9–330.5)
197.8 (81.6–246.9)
165.2 (93.2–226.4)
9.8 (4.3–15.1)
ns
1
< 0.001
2
263.3 (133.2–444.2)
300.4 (210.0–360.2)
231.1 (152.1–299.1)
Not detected
ns
3, 0.001
4
100.0
100.0
100.0
100.0
63.3
88.2
100.0
0.0
Not detected
/
/
/
47.7 (28.5–63.4)
/
/
/
0.0
35.0
60.8 (23.1–106.1)
77.5 (56.0–90.1)
64.6 (48.2–74.7)
253.0 (202.1–294.6)
ns
5
< 0.001
6
200.3 (64.3–421.2)
244.5 (211.6–288.2)
26.0 (19.5–33.1)
144.8 (122.7–164.7)
p < 0.001
7
90.0
70.0
100.0
100.0
61.0
62.0
50.0
50.0
650.0 (543.1–769.3)
/
/
/
370.6 (268.2–490.6)
/
/
/
100.0
100.0
1 Non-significant difference in CSF TNF-alpha levels for the relapse and the SPMS group.
2 Significant difference in CSF TNF-alpha levels for both the relapse and the SPMS group and the remission group.
3 Non-significant difference in plasma TNF-alpha levels for the relapse and the SPMS group.
4 Significant  difference in plasma TNF-alpha levels for both the relapse and the SPMS group and the remission group.
5 Non-significant  difference in CSF IL-4 levels for the relapse and the SPMS group.
6 Significant  difference in CSF IL-4 levels for both the relapse and the SPMS group and remission group.
7 Significant  difference in plasma IL-4 levels for all three groups.
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Fig. 1 – Correlation between cerebrospinal fluid TNF-alpha
levels and albumin ratio in the relapse multiple sclerosis
patients
Discussion
The role of TNF-alpha in MS pathogenesis is impli-
cated by several studies – it has been identified in acute and
chronic MS lesions
 22, TNF-alpha secretion from monocyte
has been shown to be higher before
 23 and during MS re-
lapse
 24 and, recently, it has been reported that increased
TNF-alpha concentrations is related to fatigue in MS
 25.
We detected TNF-alpha in CSF of all MS patients, but it
was not detected in CSF of the patients with other neurological
non-inflammatory diseases. Our findings are in concordance
with the results of Tsukada et al. 
11 and Baraczka et al.
 26.
Other authors 
8 detected TNF-alpha in a smaller percentage of
MS patients, though the studies were performed in a signifi-
cantly smaller patient group. In relation to clinical stage of
MS, TNF-alpha concentrations differ among the groups. The
highest concentration was found during the relapse phase, as
were noted in other studies
 7, 27. Rather high values of TNF-
alpha were detected in CSF of SPMS in our study, though
lower compared to relapse values. Other authors reported high
concentration of TNF-alpha in progressive MS, form as
well
 27, 28. In relation to cytokine production from peripheral
mononuclear blood cells derived from MS patients and stimu-
lated in vitro, no difference in TNF-alpha production was re-
ported in progressive and stable MS 
29. However, there is no
data related to TNF-alpha concentrations in progressive and
relapse group of MS patients within the same study and using
the same methodology. Increased TNF-alpha concentrations in
the CSF potentate inflammatory response, by augmenting
macrophage functions, production of other inflammatory cyto-
kines, lytic enzymes and reactive oxidative species (ROS).
The importance of ROS in MS is confirmed in our previously
published data
 30, 31. We reported increased index of lipid per-
oxidation both in CSF and plasma, increased concentrations of
superoxid anion radical in plasma and increased activity of
two anti-oxidative enzymes, superoxide dismutase and gluta-
tion reductase
 31.
On the other hand, in remission TNF-alpha level was
significantly lower, though still present in CSF. Shaw et al. 
32
did not find a significant difference in TNF-alpha concentra-
tions in the stable MS patients and the control group both in
CSF and sera, while Sharief et al. 
27 did not detect TNF-alpha
in CSF of the stable MS patients. Our findings support the
thesis of continuous inflammatory response within the CNS
during the MS course
 6, 28, 32. One could speculate that among
other inflammatory factors, high concentrations of TNF-
alpha in CSF is needed for clinical presentation of MS re-
lapse and/or progression of the disease.
A very recent report emphasizes the role of TNF-alpha
in relapse by finding that suppressive effect of glucocorti-
coids on TNF-alpha production is associated with its clinical
effect in MS
 33. Similar pattern of TNF-alpha production was
found in plasma of our MS patients group. High levels were
found in the relapse and SPMS group, higher than in CSF
though not significantly, while in the stable MS patients
TNF-alpha was not detected in plasma. Detectability of
TNF-alpha in plasma varies in different studies. It was de-
tected in rather small percentage
 10, or in one third of MS pa-
tients
 7. Only Sharief et al. 
27 found significantly higher con-
centrations of TNF-alpha in CSF compared to plasma. In our
group of MS patients detectebility of TNF-alpha in CSF was
100%, while in plasma it was detected in 63.3% of the MS
patients and in the control group in only 35.0% of patients.
Having in mind autocrine function of cytokine, it would not
be expected to find such high levels of TNF-alpha in plasma.
Although pathological process is within the CNS, immu-
nologicaly privileged and protected compartment, systemic
reaction is still present. High levels of TNF-alpha in plasma
might be explained by systemic reaction to stress, MS re-
lapse being powerful stressful event, especially since TNF-
alpha was not detected in plasma of stable MS patients. In
other words, during the MS course inflammatory reaction
and immunological response are not limited within the CNS,
but widespread. The results of recent studies 
34, 35 are consis-
tent with this hypothesis. Significant and sustained increase
of serum TNF-alpha was found in healthy subjects a day af-
ter a psychologically stressful event
 34. We did not find a cor-
relation between CSF values of TNF-alpha and EDSS as
others did 
23. In our study, albumin ratio, a marker of the
blood-brain barrier damage correlated with the CSF values of
TNF-alpha in the patients with relapse. No relationship was
found between the intrathecal IgG synthesis and TNF-alpha
values in plasma and CSF in our group of patients.
However, it seems that immunoregulatory role of TNF-
alpha is far more complex, since MS treatment with anti-
TNF-alpha antibodies resulted in further demielynation and
disease progression
 36.
Some studies have shown that production of IL-4 and
IL-10, both Th2 cytokines, is increased in stable
 17 and inter-
feron beta treated MS patients
 37 and reduced in clinically
active phase of MS
 38. That is in concordance with our re-
sults. In the patients with relapse and those with SPMS, IL-4
concentration in CSF was low and even undetectable in one
third of the relapse patients. On the contrary, in CSF of sta-
ble patients IL-4 concentration was significantly higher andVolumen 69, Broj 2 VOJNOSANITETSKI PREGLED Strana 155
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detected in all. However, IL-4 showed a different secretion
pattern in plasma. The highest concentration was detected in
relapse patients, than in stable patients, and the lowest in
SPMS. The secretion pattern of both cytokines, pro-
inflammatory TNF-alpha and anti-inflammatory IL-4 ap-
pears to be the same as far as plasma concentrations are con-
cerned. Relapse is characterized by high concentrations of
TNF-alpha and other inflammatory cytokines in plasma,
while high concentrations of IL-4 might be a consequence,
an effort to dampen systemic inflammatory response. Ac-
cording to our results, systemic cytokine response and cyto-
kine secretion within the CNS may not be in concordance
with the cytokine dominant function in a case of relapse or
remission, as some experimental data has shown
 39.  IL-4
shows inhibitory effect on TNF-alpha secretion and aug-
ments TNF-alpha sR production in vitro 
40, however in our
study no negative correlation was found between IL-4 and
TNF-alpha concentrations neither in CSF nor in plasma. Our
data confirm previous reports of lack of correlation between
CSF and plasma values of IL-4 and EDSS 
15. No correlation
was found either for intrathecal IgG synthesis, nor for albu-
min ratio and IL-4 plasma and CSF values, as previously re-
ported 
38.
A misbalance found between inflammatory and anti-
inflammatory cytokines, is one of many immune dysregula-
tions in MS and one should be aware of oversimplified inter-
pretation
 41.  However, these results support the thesis that
modification of cytokine profiles could be associated with
prevention of disease relapse and maintaining remission of
MS. Present therapeutic strategies in MS are shifted from
immunomodulation to more aggressive immunosupressive
treatments with monoclonal antibodies
 42. Clinical improve-
ment in those studies has been shown to correlate with de-
crease of inflammatory cytokines and increase of anti-
inflammatory cytokine production 
43–45.
Conclusion
According to our data MS relapse is characterized by
high concentration of TNF-alpha in CSF and plasma and low
concentration of IL-4 in CSF and high in plasma. Remission is
characterized by high concentration of IL-4 and low concen-
trations of TNF-alpha both in CSF and plasma. SPMS is char-
acterized with the same cytokine pattern as relapse, though
both cytokines, inflammatory TNF-alpha and anti-inflamma-
tory IL-4, have been detected in lower concentrations.
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